Effect of <italic style="font-style: italic">Shenqi Yiliu Formula</italic> （参芪抑瘤方） Drug-Containing Serum on the Cycle of Gastric Cancer Cell AGS and Wnt/β-Catenin Pathway

WEI Na; GUO Chongyuan; BAI Min; AN Yaorong; ZHANG Sichao; WU Liyang; DUAN Yongqiang

doi:10.13288/j.11-2166/r.2025.04.012

您当前的位置：

首页 >

文章列表页 >

Effect of Shenqi Yiliu Formula （参芪抑瘤方） Drug-Containing Serum on the Cycle of Gastric Cancer Cell AGS and Wnt/β-Catenin Pathway

更新时间：2025-02-18

- Effect of Shenqi Yiliu Formula （参芪抑瘤方） Drug-Containing Serum on the Cycle of Gastric Cancer Cell AGS and Wnt/β-Catenin Pathway
- Journal of Traditional Chinese Medicine Vol. 66, Issue 4, Pages: 399-406(2025)
- 作者机构：
  
  1.甘肃中医药大学甘肃省中药新产品创制工程实验室，甘肃省兰州市定西东路35号，730000
  2.甘肃省中医方药挖掘与创新转化重点实验室
  3.宁夏医科大学中医学院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2025.04.012
  CLC：
- Received：24 October 2024，
  
  Revised：2024-11-30，
  
  Published：17 February 2025
- 稿件说明：
移动端阅览
魏娜,郭崇元,白敏等.参芪抑瘤方含药血清对胃癌细胞AGS细胞周期及Wnt/β-catenin通路的影响[J].中医杂志,2025,66(04):399-406.

WEI Na,GUO Chongyuan,BAI Min,et al.Effect of Shenqi Yiliu Formula （参芪抑瘤方） Drug-Containing Serum on the Cycle of Gastric Cancer Cell AGS and Wnt/β-Catenin Pathway[J].Journal of Traditional Chinese Medicine,2025,66(04):399-406.
魏娜,郭崇元,白敏等.参芪抑瘤方含药血清对胃癌细胞AGS细胞周期及Wnt/β-catenin通路的影响[J].中医杂志,2025,66(04):399-406. DOI： 10.13288/j.11-2166/r.2025.04.012.

WEI Na,GUO Chongyuan,BAI Min,et al.Effect of Shenqi Yiliu Formula （参芪抑瘤方） Drug-Containing Serum on the Cycle of Gastric Cancer Cell AGS and Wnt/β-Catenin Pathway[J].Journal of Traditional Chinese Medicine,2025,66(04):399-406. DOI： 10.13288/j.11-2166/r.2025.04.012.

摘要

目的

从无翅型MMTV整合位点家族成员（Wnt）/β-连环蛋白（β-catenin）通路探讨参芪抑瘤方治疗胃癌前病变（PLGC）的可能作用机制。

方法

采用CCK-8法检测胃癌细胞AGS细胞存活率筛选参芪抑瘤方含药血清干预时间及Wnt/β-catenin通路抑制剂XAV939干预浓度。实验将AGS细胞分为胃癌细胞组（15%空白血清）、抑制剂组（筛选浓度的XAV939）、参芪抑瘤方高剂量组（12%参芪抑瘤方含药血清+3%空白血清）、参芪抑瘤方中剂量组（6%参芪抑瘤方含药血清+9%空白血清）、参芪抑瘤方低剂量组（3%参芪抑瘤方含药血清+12%空白血清），每组设3个

复孔。分别培养24 h、48 h通过细胞划痕实验检测细胞迁移、侵袭能力；培养筛选干预时间后流式细胞术检测细胞周期，荧光免疫法检测增殖细胞核抗原（Ki67）蛋白水平，蛋白免疫印记法检测Wnt、β-catenin、糖原合成酶激酶3β（GSK-3β）、核内T细胞特异性因子（TCF）蛋白水平，实时荧光定量PCR法检测

Wnt

、

catenin

、

GSK

3β

、

TCF

mRNA表达。

结果

筛选出参芪抑瘤方含药血清干预时间为48 h和XAV939干预浓度为20 μmol/L用于后续实验。与胃癌细胞组同时间点比较，除24 h参芪抑瘤方低剂量组之外，参芪抑瘤方各剂量组24 h、48 h细胞划痕迁移率均降低（

＜0.05）。与参芪抑瘤方低剂量组同时间点比较，参芪抑瘤方高、中剂量组24 h及参芪抑瘤方高剂量组48 h细胞划痕迁移率均降低（

＜0.05）。与胃癌细胞组比较，参芪抑瘤方高剂量组和抑制剂组Wnt、β-catenin、TCF蛋白水平及其相应的mRNA表达降低，Ki67蛋白水平及细胞周期S期、G2期比例亦降低，GSK-3β蛋白水平、

GSK

3β

mRNA表达及G1期比例升高（

＜0.05）。与抑制剂组比较，参芪抑瘤方高剂量组G1期比例降低、G2期比例升高（

＜0.05），而Wnt、β-catenin蛋白水平其相应的mRNA表达差异无统计学意义（

＞0.05）。

结论

参芪抑瘤方含药血清可以抑制胃癌细胞AGS的迁移、侵袭能力，将细胞周期阻滞在G1期，其机制可能与调控Wnt/β-catenin通路有关。

Abstract

Objective

To investigate the potential mechanism of

Shenqi Yiliu Formula

（参芪抑瘤方） in treating precancerous lesions of gastric cancer （PLGC） by the Wnt/β-catenin signaling pathway.

Methods

The CCK-8 assay was used to determine the optimal intervention time for

Shenqi Yiliu Formula

drug-containing serum and the concentration of the Wnt/β-catenin pathway inhibitor XAV939 depends on the survival rate of AGS gastric cancer cell line. AGS cells were divided into the gastric cancer cell group （15% blank serum）， inhibitor group （selected concentration of XAV939）， high-dose

Shenqi Yiliu Formula

group （12%

Shenqi Yiliu Formula

drug-containing serum + 3% blank serum）， medium-dose

Shenqi Yiliu Formula

group （6%

Shenqi Yiliu Formula

drug-containing serum + 9% blank serum）， and low-dose

Shenqi Yiliu Formula

group （3%

Shenqi Yiliu Formula

drug-conta

ining serum + 12% blank serum）. Each group was tested in triplicate. After culturing for 24 and 48 hours， cell migration and invasion were assessed by scratch assays； after a selected intervention period （48 hours）， cell cycle distribution was analyzed using flow cytometry， Ki67 protein levels were detected by immunofluorescence， the protein levels of Wnt， β-catenin， GSK-3β， and intranuclear T-cell specific factor（TCF） were measured by the protein immunoblotting assay， and the mRNA expressions of these above factors were determined by quantitative real-time PCR.

Results

The optimal intervention time for

Shenqi Yiliu Formula

drug-containing serum was determined to be 48 hours， and the effective concentration of XAV939 was 20 μmol/L. Compared with the gastric cancer cell group，

Shenqi Yiliu Formula

at all doses reduced the cell migration rate at 24 and 48 hours （

＜0.05）， except for the low-dose group at 24 hours. Compared to the low-dose group at corresponding time points， high- and medium-dose

Shenqi Yiliu Formula

groups showed significantly reduced migration rates， particularly the high-dose group at 48 hours （

＜0.05）. Compared with the gastric cancer cell group， the high-dose

Shenqi Yiliu Formula

and inhibitor groups exhibited reduced protein and mRNA levels of Wnt， β-catenin， and TCF， along with reduced Ki67 protein levels and a decreased proportion of cells in the S and G2 phases of the cell cycle， but GSK-3β protein levels，

GSK

3β

mRNA expression， and the proportion of cells in the G1 phase increased （

＜0.05）. Compared to the inhibitor group， the high-dose

Shenqi Yiliu Formula

group showed a decreased proportion of G1-phase cells and an increased proportion of G2-phase cells （

＜0.05）， although differences in Wnt and β-catenin protein levels and mRNA expressions were not statistically significant

（

＞0.05）.

Conclusion

Shenqi Yiliu Formula

drug-containing serum inhibits the migration and invasion of gastric cancer AGS cells and block the cell cycle at G1 phase， and its underlying mechanism may be related to the regulation of the Wnt/β-catenin signaling pathway.

关键词

Keywords

references

WANG FH ， ZHANG XT ， LI YF ， et al . The Chinese Society of Clinical Oncology （CSCO）： clinical guidelines for the diagnosis and treatment of gastric cancer ［J］. Cancer Commun （Lond）， 2021 ， 41 （ 8 ）： 747 - 795 .

XU W ， LI B ， XU M ， et al . Traditional Chinese medicine for precancerous lesions of gastric cancer： a review ［J］. Biomed Pharmacother ， 2022 ， 146 ： 112542 . doi： 10.1016/j.biopha.2021.112542 http://dx.doi.org/10.1016/j.biopha.2021.112542 .

中华医学会消化病学分会幽门螺杆菌学组 . 第六次全国幽门螺杆菌感染处理共识报告（非根除治疗部分）［J］. 胃肠病学， 2022 ， 27 （ 5 ）： 289 - 304 .

齐姗姗，王旭旭，武纪生，等 . 参芪抑瘤方联合幽门螺杆菌根治方案对幽门螺杆菌阳性胃癌前病变患者疗效及血清GAS、TRX-1、C-myc蛋白表达影响［J］. 辽宁中医药大学学报， 2020 ， 22 （ 2 ）： 194 - 197 .

马春林，吴红彦，李海龙，等 . 参芪抑瘤方药物血清对胃癌MGC-803细胞增殖的影响［J］. 中国中医药信息杂志， 2017 ， 24 （ 3 ）： 53 - 56 .

CHEN J ， WANG X ， ZHANG J ， et al . Effects of the Wnt/β-catenin signaling pathway on proliferation and apoptosis of gastric cancer cells ［J］. Contrast Media Mol Imaging ， 2023 ， 2023 ： 9824340 . doi： 10.1155/2023/9824340 http://dx.doi.org/10.1155/2023/9824340 .

施新猷 . 现代医学实验动物学［M］. 北京：人民军医出版社， 2000 ： 612 .

张瑞芬，王智业，党林林，等 . 慢性萎缩性胃炎中医病因病机及证候分型的研究近况［J］. 中医临床研究， 2022 ， 14 （ 6 ）： 86 - 88，96 .

ZENG Z ， NIAN Q ， CHEN N ， et al . Ginsenoside Rg3 inhibits angiogenesis in gastric precancerous lesions through downregulation of Glut1 and Glut4 ［J］. Biomed Pharmacother ， 2022 ， 145 ： 112086 . doi： 10.1016/j.biopha.2021.112086 http://dx.doi.org/10.1016/j.biopha.2021.112086 .

WU Q ， MA J ， WEI J ， et al . lncRNA SNHG11 promotes gastric cancer progression by activating the Wnt/β-catenin path way and oncogenic autophagy ［J］. Mol Ther ， 2021 ， 29 （ 3 ）： 1258 - 1278 .

SUNG H ， FERLAY J ， SIEGEL RL ， et al . Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

LIAO W ， WEN Y ， WANG J ， et al . Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway ［J］. J Ethnopharmacol ， 2023 ， 302 （ Pt A ）： 115885 . doi： 10.1016/j.jep.2022.115885 http://dx.doi.org/10.1016/j.jep.2022.115885 .

ZHU Y ， WANG J ， WANG J ， et al . Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions ［J］. Saudi Med J ， 2023 ， 44 （ 8 ）： 795 - 800 .

ZHANG SX ， TIAN W ， LIU YL ， et al . Mechanism of N-Methyl-N-Nitroso-Urea-Induced gastric precancerous lesions in mice ［J］. J Oncol ， 2022 ， 2022 ： 3780854 . doi： 10.1155/2022/3780854 http://dx.doi.org/10.1155/2022/3780854 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Jianpi Yishen Huatan Formula （健脾益肾化痰方）-Medicated Serum on Apoptosis，Migration and the LncRNA ALAL-1/USP4/HDAC2 Pathway in Human Lung Squamous Carcinoma Cells

Discussion on Treatment of Gastric "Inflammation-cancer" Transformation based on the "Five-view Differentiation and Treatment" System

Effect of Jianpi Yiqi Shexue Formula （健脾益气摄血方） on Intestinal Immunity in Primary Immune Thrombocytopenia Model Mice

Effect of Carthamin on the Cell Migration Induced by Modeled Microgravity

Effect of Keliu Pill on the Apoptosis and Cell Cycle of Human Colon Carcinoma Cell Line HT-29

Related Author

FANG Yijun

WANG Xuemei

XIONG Changzhou

LI Liubang

QIN Huimin

WANG Zhiguang

GE Yuansha

XU Bowen

Related Institution

The First Affiliated Hospital of Guangxi University of Chinese Medicine

Graduate School，Guangxi University of Chinese Medicine

Beijing University of Chinese Medicine

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Xi'an Medical University

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Effect of Shenqi Yiliu Formula （参芪抑瘤方） Drug-Containing Serum on the Cycle of Gastric Cancer Cell AGS and Wnt/β-Catenin Pathway

DOI：10.13288/j.11-2166/r.2025.04.012

摘要

Abstract

关键词

Keywords

references